{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:34:21Z","timestamp":1784237661724,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The prognosis of advanced biliary tract cancer (BTC) patients remains poor due to limited efficacy of chemotherapy and difficulties in management. Thus, prediction of survival is crucial for the clinical management of advanced BTC. The aim was to develop and validate a nomogram to predict 6-month and 12-month survival in advanced BTC patients treated with chemotherapy. A multivariable Cox regression model was used to construct a nomogram in a training set (JCOG1113, a phase III trial comparing gemcitabine plus S-1 [GS] and gemcitabine plus cisplatin, n\u2009=\u2009351). External validity of the nomogram was assessed using a test set (JCOG0805, a randomized, phase II trial comparing GS and S-1 alone, n\u2009=\u2009100). Predictive performance was assessed in terms of discrimination and calibration. The constructed nomogram included lymph node metastasis, liver metastasis, carbohydrate antigen 19-9, carcinoembryonic antigen, albumin, and C-reactive protein. Uno\u2019s concordance index was 0.661 (95% confidence interval [CI] 0.629\u20130.696) in the training set and 0.640 (95% CI 0.566\u20130.715) in the test set. The calibration plots for 6-month and 12-month survival showed good agreement in the two analysis sets. The present nomogram can facilitate prediction of the prognosis of advanced BTC patients treated with chemotherapy and help clinicians\u2019 prognosis-based decision-making.<\/jats:p>","DOI":"10.1038\/s41598-023-48889-6","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T12:02:55Z","timestamp":1701864175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development of a nomogram to predict survival in advanced biliary tract cancer"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0584-0095","authenticated-orcid":false,"given":"Hiroshi","family":"Imaoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Sugimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumasa","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohei","family":"Satoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihito","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keji","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Asagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"48889_CR1","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/cncr.33476","volume":"127","author":"G Ouyang","year":"2021","unstructured":"Ouyang, G. et al. The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: A systematic analysis for the Global Burden of Disease Study 2017. Cancer 127, 2238\u20132250. https:\/\/doi.org\/10.1002\/cncr.33476 (2021).","journal-title":"Cancer"},{"key":"48889_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"48889_CR3","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1002\/cncr.30074","volume":"122","author":"JA Flemming","year":"2016","unstructured":"Flemming, J. A., Zhang-Salomons, J., Nanji, S. & Booth, C. M. Increased incidence but improved median overall survival for biliary tract cancers diagnosed in Ontario from 1994 through 2012: A population-based study. Cancer 122, 2534\u20132543. https:\/\/doi.org\/10.1002\/cncr.30074 (2016).","journal-title":"Cancer"},{"key":"48889_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/s0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle, J. W., Kelley, R. K., Nervi, B., Oh, D.-Y. & Zhu, A. X. Biliary tract cancer. The Lancet 397, 428\u2013444. https:\/\/doi.org\/10.1016\/s0140-6736(21)00153-7 (2021).","journal-title":"The Lancet"},{"key":"48889_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362, 1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721 (2010).","journal-title":"N. Engl. J. Med."},{"key":"48889_CR6","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/cam4.299","volume":"3","author":"F Fiteni","year":"2014","unstructured":"Fiteni, F. et al. Cisplatin\/gemcitabine or oxaliplatin\/gemcitabine in the treatment of advanced biliary tract cancer: A systematic review. Cancer Med. 3, 1502\u20131511. https:\/\/doi.org\/10.1002\/cam4.299 (2014).","journal-title":"Cancer Med."},{"key":"48889_CR7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/annonc\/mdz058","volume":"30","author":"ST Kim","year":"2019","unstructured":"Kim, S. T. et al. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: A multicenter, open-label, randomized, phase III, noninferiority trial. Ann. Oncol. 30, 788\u2013795. https:\/\/doi.org\/10.1093\/annonc\/mdz058 (2019).","journal-title":"Ann. Oncol."},{"key":"48889_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/s1470-2045(11)70301-1","volume":"13","author":"J Lee","year":"2012","unstructured":"Lee, J. et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 13, 181\u2013188. https:\/\/doi.org\/10.1016\/s1470-2045(11)70301-1 (2012).","journal-title":"Lancet Oncol."},{"key":"48889_CR9","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane, C. et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann. Oncol. 30, 1950\u20131958. https:\/\/doi.org\/10.1093\/annonc\/mdz402 (2019).","journal-title":"Ann. Oncol."},{"key":"48889_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.1219","author":"T Ioka","year":"2022","unstructured":"Ioka, T. et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). J. Hepatobiliary Pancreat. Sci. https:\/\/doi.org\/10.1002\/jhbp.1219 (2022).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"48889_CR11","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","author":"D-Y Oh","year":"2022","unstructured":"Oh, D.-Y. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. https:\/\/doi.org\/10.1056\/EVIDoa2200015 (2022).","journal-title":"NEJM Evid."},{"key":"48889_CR12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.14309\/ajg.0000000000001151","volume":"116","author":"D Kim","year":"2021","unstructured":"Kim, D., Konyn, P., Cholankeril, G., Bonham, C. A. & Ahmed, A. Trends in the mortality of biliary tract cancers based on their anatomical site in the United States from 2009 to 2018. Am. J. Gastroenterol. 116, 1053\u20131062. https:\/\/doi.org\/10.14309\/ajg.0000000000001151 (2021).","journal-title":"Am. J. Gastroenterol."},{"key":"48889_CR13","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/annonc\/mdv253","volume":"26","author":"T Grenader","year":"2015","unstructured":"Grenader, T. et al. Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: The ABC-02 and BT-22 studies. Ann. Oncol. 26, 1910\u20131916. https:\/\/doi.org\/10.1093\/annonc\/mdv253 (2015).","journal-title":"Ann. Oncol."},{"key":"48889_CR14","doi-asserted-by":"publisher","first-page":"133139","DOI":"10.3390\/cancers13133139","volume":"13","author":"CE Wu","year":"2021","unstructured":"Wu, C. E. et al. Establishment of a pretreatment nomogram to predict the 6-month mortality rate of patients with advanced biliary tract cancers undergoing gemcitabine-based chemotherapy. Cancers 13, 133139. https:\/\/doi.org\/10.3390\/cancers13133139 (2021).","journal-title":"Cancers"},{"key":"48889_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00535-018-1518-3","volume":"54","author":"Y Suzuki","year":"2019","unstructured":"Suzuki, Y. et al. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy. J. Gastroenterol. 54, 281\u2013290. https:\/\/doi.org\/10.1007\/s00535-018-1518-3 (2019).","journal-title":"J. Gastroenterol."},{"key":"48889_CR16","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1002\/cncr.24472","volume":"115","author":"I Park","year":"2009","unstructured":"Park, I. et al. Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. Cancer 115, 4148\u20134155. https:\/\/doi.org\/10.1002\/cncr.24472 (2009).","journal-title":"Cancer"},{"key":"48889_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00280-010-1360-7","volume":"67","author":"T Sasaki","year":"2011","unstructured":"Sasaki, T. et al. Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. Cancer Chemother. Pharmacol. 67, 847\u2013853. https:\/\/doi.org\/10.1007\/s00280-010-1360-7 (2011).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"48889_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejca.2019.05.030","volume":"117","author":"M Salati","year":"2019","unstructured":"Salati, M. et al. The ALAN score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. Eur. J. Cancer 117, 84\u201390. https:\/\/doi.org\/10.1016\/j.ejca.2019.05.030 (2019).","journal-title":"Eur. J. Cancer"},{"key":"48889_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression Modeling Strategies","author":"FE Harrell Jr","year":"2015","unstructured":"Harrell, F. E. Jr. Regression Modeling Strategies (Springer, 2015)."},{"key":"48889_CR20","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/cas.12218","volume":"104","author":"C Morizane","year":"2013","unstructured":"Morizane, C. et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: A Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 104, 1211\u20131216. https:\/\/doi.org\/10.1111\/cas.12218 (2013).","journal-title":"Cancer Sci."},{"key":"48889_CR21","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/bju.13573","volume":"119","author":"JJ Tosoian","year":"2017","unstructured":"Tosoian, J. J. et al. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era. BJU Int. 119, 676\u2013683. https:\/\/doi.org\/10.1111\/bju.13573 (2017).","journal-title":"BJU Int."},{"key":"48889_CR22","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/jso.24569","volume":"115","author":"G Spolverato","year":"2017","unstructured":"Spolverato, G. et al. Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. J. Surg. Oncol. 115, 696\u2013703. https:\/\/doi.org\/10.1002\/jso.24569 (2017).","journal-title":"J. Surg. Oncol."},{"key":"48889_CR23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.4143\/crt.2016.538","volume":"49","author":"HS Park","year":"2017","unstructured":"Park, H. S. et al. Prognostic factors and scoring model for survival in metastatic biliary tract cancer. Cancer Res. Treat. 49, 1127\u20131139. https:\/\/doi.org\/10.4143\/crt.2016.538 (2017).","journal-title":"Cancer Res. Treat."},{"key":"48889_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejca.2008.08.024","volume":"45","author":"CD Briggs","year":"2009","unstructured":"Briggs, C. D. et al. Prognostic molecular markers in cholangiocarcinoma: A systematic review. Eur. J. Cancer 45, 33\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.08.024 (2009).","journal-title":"Eur. J. Cancer"},{"key":"48889_CR25","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","volume":"76","author":"L Izquierdo-Sanchez","year":"2022","unstructured":"Izquierdo-Sanchez, L. et al. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA registry. J. Hepatol. 76, 1109\u20131121. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.010 (2022).","journal-title":"J. Hepatol."},{"key":"48889_CR26","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1200\/JCO.21.02568","volume":"40","author":"J Bridgewater","year":"2022","unstructured":"Bridgewater, J. et al. Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study. J. Clin. Oncol. 40, 2048\u20132057. https:\/\/doi.org\/10.1200\/JCO.21.02568 (2022).","journal-title":"J. Clin. Oncol."},{"key":"48889_CR27","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423\u20131437. https:\/\/doi.org\/10.1038\/nm.3394 (2013).","journal-title":"Nat. Med."},{"key":"48889_CR28","doi-asserted-by":"publisher","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"RJ DeBerardinis","year":"2016","unstructured":"DeBerardinis, R. J. & Chandel, N. S. Fundamentals of cancer metabolism. Sci. Adv. 2, e1600200. https:\/\/doi.org\/10.1126\/sciadv.1600200 (2016).","journal-title":"Sci. Adv."},{"key":"48889_CR29","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","volume":"39","author":"DC McMillan","year":"2013","unstructured":"McMillan, D. C. The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer Treat. Rev. 39, 534\u2013540. https:\/\/doi.org\/10.1016\/j.ctrv.2012.08.003 (2013).","journal-title":"Cancer Treat. Rev."},{"key":"48889_CR30","doi-asserted-by":"publisher","first-page":"e22684","DOI":"10.1002\/jcla.22684","volume":"33","author":"JH Du","year":"2019","unstructured":"Du, J. H. & Lu, J. Circulating CEA-dNLR score predicts clinical outcome of metastatic gallbladder cancer patient. J. Clin. Lab. Anal. 33, e22684. https:\/\/doi.org\/10.1002\/jcla.22684 (2019).","journal-title":"J. Clin. Lab. Anal."},{"key":"48889_CR31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s12029-021-00596-z","volume":"53","author":"G Rovesti","year":"2022","unstructured":"Rovesti, G. et al. Prognostic role of a new index tested in European and Korean advanced biliary tract cancer patients: The PECS index. J. Gastrointest. Cancer 53, 289\u2013298. https:\/\/doi.org\/10.1007\/s12029-021-00596-z (2022).","journal-title":"J. Gastrointest. Cancer"},{"key":"48889_CR32","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/s1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca, A. et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial. Lancet Oncol. 22, 690\u2013701. https:\/\/doi.org\/10.1016\/s1470-2045(21)00027-9 (2021).","journal-title":"Lancet Oncol."},{"key":"48889_CR33","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/s1470-2045(20)30321-1","volume":"21","author":"V Subbiah","year":"2020","unstructured":"Subbiah, V. et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 21, 1234\u20131243. https:\/\/doi.org\/10.1016\/s1470-2045(20)30321-1 (2020).","journal-title":"Lancet Oncol."},{"key":"48889_CR34","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/s1470-2045(21)00336-3","volume":"22","author":"M Javle","year":"2021","unstructured":"Javle, M. et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 22, 1290\u20131300. https:\/\/doi.org\/10.1016\/s1470-2045(21)00336-3 (2021).","journal-title":"Lancet Oncol."},{"key":"48889_CR35","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","volume":"40","author":"A Ohba","year":"2022","unstructured":"Ohba, A. et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial). J. Clin. Oncol. 40, 4006\u20134006. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4006 (2022).","journal-title":"J. Clin. Oncol."},{"key":"48889_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30157-1","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa, G. K. et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. https:\/\/doi.org\/10.1016\/s1470-2045(20)30157-1 (2020).","journal-title":"Lancet Oncol."},{"key":"48889_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30109-1","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. Lancet Oncol. https:\/\/doi.org\/10.1016\/s1470-2045(20)30109-1 (2020).","journal-title":"Lancet Oncol."},{"key":"48889_CR38","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","volume":"12","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam, F. et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: A phase I dose-expansion study. Cancer Discov. 12, 402\u2013415. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0697 (2022).","journal-title":"Cancer Discov."},{"key":"48889_CR39","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/s2468-1253(21)00196-5","volume":"6","author":"M Javle","year":"2021","unstructured":"Javle, M. et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol. Hepatol. 6, 803\u2013815. https:\/\/doi.org\/10.1016\/s2468-1253(21)00196-5 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"48889_CR40","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","volume":"120","author":"V Mazzaferro","year":"2019","unstructured":"Mazzaferro, V. et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br. J. Cancer 120, 165\u2013171. https:\/\/doi.org\/10.1038\/s41416-018-0334-0 (2019).","journal-title":"Br. J. Cancer"},{"key":"48889_CR41","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","volume":"25","author":"R Bahleda","year":"2019","unstructured":"Bahleda, R. et al. Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin. Cancer Res. 25, 4888\u20134897. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3334 (2019).","journal-title":"Clin. Cancer Res."},{"key":"48889_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jco.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: Results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 38, 1\u201310. https:\/\/doi.org\/10.1200\/jco.19.02105 (2020).","journal-title":"J. Clin. Oncol."},{"key":"48889_CR43","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/SLA.0b013e31818a1561","volume":"248","author":"M Kayahara","year":"2008","unstructured":"Kayahara, M., Nagakawa, T., Nakagawara, H., Kitagawa, H. & Ohta, T. Prognostic factors for gallbladder cancer in Japan. Ann. Surg. 248, 807\u2013814. https:\/\/doi.org\/10.1097\/SLA.0b013e31818a1561 (2008).","journal-title":"Ann. Surg."},{"key":"48889_CR44","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1245\/s10434-010-0938-y","volume":"17","author":"SY Cho","year":"2010","unstructured":"Cho, S. Y. et al. Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann. Surg. Oncol. 17, 1823\u20131830. https:\/\/doi.org\/10.1245\/s10434-010-0938-y (2010).","journal-title":"Ann. Surg. Oncol."},{"key":"48889_CR45","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1177\/000313481007601130","volume":"76","author":"XD He","year":"2010","unstructured":"He, X. D. et al. Gender-specific prognostic markers of patients with gallbladder cancer after surgical resection. Am. Surg. 76, 1269\u20131274 (2010).","journal-title":"Am. Surg."},{"key":"48889_CR46","doi-asserted-by":"publisher","first-page":"e15095","DOI":"10.1200\/jco.2014.32.15_suppl.e15095","volume":"32","author":"V Gupta","year":"2014","unstructured":"Gupta, V. et al. Sex-based differences in gallbladder cancer: An analysis of 257 patients. J. Clin. Oncol. 32, e15095. https:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.e15095 (2014).","journal-title":"J. Clin. Oncol."},{"key":"48889_CR47","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJMoa021423","volume":"348","author":"EE Calle","year":"2003","unstructured":"Calle, E. E., Rodriguez, C., Walker-Thurmond, K. & Thun, M. J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N. Engl. J. Med. 348, 1625\u20131638. https:\/\/doi.org\/10.1056\/NEJMoa021423 (2003).","journal-title":"N. Engl. J. Med."},{"key":"48889_CR48","doi-asserted-by":"publisher","first-page":"e0195118","DOI":"10.1371\/journal.pone.0195118","volume":"13","author":"J Kang","year":"2018","unstructured":"Kang, J. et al. Body mass index and weight change during initial period of chemotherapy affect survival outcome in advanced biliary tract cancer patients. PLoS ONE 13, e0195118. https:\/\/doi.org\/10.1371\/journal.pone.0195118 (2018).","journal-title":"PLoS ONE"},{"key":"48889_CR49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jhbp.314","volume":"23","author":"S Ishihara","year":"2016","unstructured":"Ishihara, S. et al. Biliary tract cancer registry in Japan from 2008 to 2013. J. Hepatobiliary Pancreat. Sci. 23, 149\u2013157. https:\/\/doi.org\/10.1002\/jhbp.314 (2016).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"48889_CR50","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","volume":"149","author":"MN Mavros","year":"2014","unstructured":"Mavros, M. N., Economopoulos, K. P., Alexiou, V. G. & Pawlik, T. M. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: Systematic review and meta-analysis. JAMA Surg. 149, 565\u2013574. https:\/\/doi.org\/10.1001\/jamasurg.2013.5137 (2014).","journal-title":"JAMA Surg."},{"key":"48889_CR51","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cncr.29686","volume":"122","author":"Y Sakamoto","year":"2016","unstructured":"Sakamoto, Y. et al. Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. Cancer 122, 61\u201370. https:\/\/doi.org\/10.1002\/cncr.29686 (2016).","journal-title":"Cancer"},{"key":"48889_CR52","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/sj.bjc.6606087","volume":"104","author":"MJ Proctor","year":"2011","unstructured":"Proctor, M. J. et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: A Glasgow inflammation outcome study. Br. J. Cancer 104, 726\u2013734. https:\/\/doi.org\/10.1038\/sj.bjc.6606087 (2011).","journal-title":"Br. J. Cancer"},{"key":"48889_CR53","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M14-0698","volume":"162","author":"KG Moons","year":"2015","unstructured":"Moons, K. G. et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): Explanation and elaboration. Ann. Intern. Med. 162, W1\u2013W73. https:\/\/doi.org\/10.7326\/M14-0698 (2015).","journal-title":"Ann. Intern. Med."},{"key":"48889_CR54","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.0006-341X.2005.030814.x","volume":"61","author":"PJ Heagerty","year":"2005","unstructured":"Heagerty, P. J. & Zheng, Y. Survival model predictive accuracy and ROC curves. Biometrics 61, 92\u2013105. https:\/\/doi.org\/10.1111\/j.0006-341X.2005.030814.x (2005).","journal-title":"Biometrics"},{"key":"48889_CR55","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/sim.4154","volume":"30","author":"H Uno","year":"2011","unstructured":"Uno, H., Cai, T., Pencina, M. J., D\u2019Agostino, R. B. & Wei, L. J. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat. Med. 30, 1105\u20131117. https:\/\/doi.org\/10.1002\/sim.4154 (2011).","journal-title":"Stat. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48889-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48889-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48889-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T12:21:44Z","timestamp":1701865304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48889-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["48889"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-48889-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3122697\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]},"assertion":[{"value":"29 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HI has received research funding from Ono Pharmaceutical; honoraria from Nihon Servier, Yakult Honsha, AstraZeneca, Kaneka Medix, and Medico's Hirata; and is a member of advisory board for Nihon Servier. MI has received research funding from Eisai, Merck biopharma, Eli Lilly Japan, Yakult, Ono Pharmaceutical, ASLAN, J-Pharma, AstraZeneca, Pfizer, Merus N.V., Nihon Servier, Delta-Fly Pharma, Chiome Bioscience, Chugai, Bristol-Myers Squibb, Novartis, Bayer, Takeda, MSD, and Syneos Health; and honoraria from Eisai, MSD, Eli Lilly Japan, Yakult, Teijin Pharma, Astellas, Sumitomo Dainippon, Otsuka, Nihon Servier, Taiho, Chugai, Bristol-Myers Squibb, Novartis, Bayer, Takeda, EA Pharma, AstraZeneca, AbbVie, Abbott Japan, Fujifilm Toyama Chemical, and Incyte Biosciences Japan. CM has received research funding from Eisai, Yakult Honsha, Ono Pharmaceutical, Taiho Pharmaceutical, J-Pharma, AstraZeneca, Merck biopharma, Daiichi Sankyo, and HITACHI; consulting fees from Yakult Honsha, MSD K.K., and Servier; and honoraria from Novartis, Yakult Honsha, Teijin Pharma, Taiho Pharmaceutical, Eisai, and MSD K.K. TO has received research funding from AstraZeneca, Syneos Health, EP clude, Eisai, MSD, and Insight Japan; consulting fees from AstraZeneca, Eisai, Nihon Servier, Dainippon Sumitomo Pharma, Bristol-Myers, and FUJIFILM Toyama Chemical; and honoraria from AstraZeneca, Insight Japan, Eisai, Ono Pharmaceutical, Yakult Honsha, Johnson & Johnson, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical, Nihon Servier, Nippon Shinyaku, Eli Lilly Japan, Pfizer Japan, and Novartis Pharma. MO has received honoraria from Taiho Pharmaceutical, MSD, Nihon Servier, Pfizer, Yakult Honsha, Ono Pharmaceutical, and Bayer. SS has received research funding from AstraZeneca, Incyte Corporation, and Delta-Fly Pharma. NO has received honoraria from Taiho Pharmaceutical, li Lilly Japan, Eisai, Bayer Yakuhin, Chugai Pharma, Ono Pharmaceutical, Takeda, and Daiichi Sankyo; and is a member of advisory board for GlaxoSmithKline. NM has received research funding from Yakult Honsha, Novartis, MSD, ASLAN Pharmaceuticals, Incyte, Ono Pharmaceutical, Seagen, Taiho Pharmaceutical, and Dainippon Sumitomo Pharma; and honoraria from Yakult Honsha, AstraZeneca, Novartis, FUJIFILM Toyama Chemical, and MSD; and is a member of advisory board for AstraZeneca. SS has received research funding from Nihon Servier; and honoraria from Nihon Servier. HY has received honoraria from Bristol-Myers Squib, Ono Pharmaceutical, Taiho Pharmaceutical, Chugai Pharmaceutical, and Eli Lilly Japan. KN has received honoraria from Yakult Honsha and Daiich Sankyo. MU has received research funding from Taiho Pharmaceutical, AstraZeneca, Merck Biopharma, MSD, Astellas Pharma, Eisai, Ono Pharmaceutical, Incyte, Chugai Pharmaceutical, DFP, Daiichi Sankyo, Novartis, and Boehringer Ingelheim; and honoraria from Taiho Pharmaceutical, AstraZeneca, Yakult Honsha, MSD, Nihon Servier, Ono Pharmaceutical, Incyte, Chugai Pharmaceutical, and Boehringer Ingelheim. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21548"}}